{
 "awd_id": "1265141",
 "agcy_id": "NSF",
 "tran_type": "Grant",
 "awd_istr_txt": "Standard Grant",
 "awd_titl_txt": "I-Corps:  Highly Sensitive Multiple Biomarker Biosensor",
 "cfda_num": "47.084",
 "org_code": "15030000",
 "po_phone": null,
 "po_email": "",
 "po_sign_block_name": "Rathindra DasGupta",
 "awd_eff_date": "2012-10-01",
 "awd_exp_date": "2013-03-31",
 "tot_intn_awd_amt": 50000.0,
 "awd_amount": 50000.0,
 "awd_min_amd_letter_date": "2012-09-26",
 "awd_max_amd_letter_date": "2012-09-26",
 "awd_abstract_narration": "Researchers plan to further develop a biosensor prototype device in order to prepare it for possible future use in medical and research fields. This prototype is an Enzyme Linked Immunosorbent Assay based biosensor that is capable of simultaneously detecting very low concentrations of various biomarkers with minimal false positives and false negatives. If successful, this will lay the foundation for early detection and monitoring of colorectal cancer that can potentially save lives and improve healthcare. \r\n\r\nFurther development of the biosensor could lead to impacts in the pharmaceutical and biotechnological fields through advanced technologies of drug development and therapeutics. Additionally, if successful, the biosensor will demonstrate the effectiveness of nanotechnology approaches to overcome diagnostic challenges. This technology could aid medical professionals by furthering their knowledge on how to address low sensitivity and high specificity detection of diseases in their early stages.",
 "awd_arra_amount": 0.0,
 "dir_abbr": "TIP",
 "org_dir_long_name": "Directorate for Technology, Innovation, and Partnerships",
 "div_abbr": "TI",
 "org_div_long_name": "Translational Impacts",
 "awd_agcy_code": "4900",
 "fund_agcy_code": "4900",
 "pi": [
  {
   "pi_role": "Principal Investigator",
   "pi_first_name": "Ahmed",
   "pi_last_name": "Busnaina",
   "pi_mid_init": "A",
   "pi_sufx_name": "",
   "pi_full_name": "Ahmed A Busnaina",
   "pi_email_addr": "busnaina@coe.neu.edu",
   "nsf_id": "000365221",
   "pi_start_date": "2012-09-26",
   "pi_end_date": null
  }
 ],
 "inst": {
  "inst_name": "Northeastern University",
  "inst_street_address": "360 HUNTINGTON AVE",
  "inst_street_address_2": "",
  "inst_city_name": "BOSTON",
  "inst_state_code": "MA",
  "inst_state_name": "Massachusetts",
  "inst_phone_num": "6173735600",
  "inst_zip_code": "021155005",
  "inst_country_name": "United States",
  "cong_dist_code": "07",
  "st_cong_dist_code": "MA07",
  "org_lgl_bus_name": "NORTHEASTERN UNIVERSITY",
  "org_prnt_uei_num": "",
  "org_uei_num": "HLTMVS2JZBS6"
 },
 "perf_inst": {
  "perf_inst_name": "Northeastern University",
  "perf_str_addr": "360 Huntington Ave.",
  "perf_city_name": "Boston",
  "perf_st_code": "MA",
  "perf_st_name": "Massachusetts",
  "perf_zip_code": "021155005",
  "perf_ctry_code": "US",
  "perf_cong_dist": "07",
  "perf_st_cong_dist": "MA07",
  "perf_ctry_name": "United States",
  "perf_ctry_flag": "1"
 },
 "pgm_ele": [
  {
   "pgm_ele_code": "802300",
   "pgm_ele_name": "I-Corps"
  }
 ],
 "pgm_ref": null,
 "app_fund": [
  {
   "app_code": "0112",
   "app_name": "NSF RESEARCH & RELATED ACTIVIT",
   "app_symb_id": "040100",
   "fund_code": "01001213DB",
   "fund_name": "NSF RESEARCH & RELATED ACTIVIT",
   "fund_symb_id": "040100"
  }
 ],
 "oblg_fy": [
  {
   "fund_oblg_fiscal_yr": 2012,
   "fund_oblg_amt": 50000.0
  }
 ],
 "por": {
  "por_cntn": "<div class=\"porColContainerWBG\">\n<div class=\"porContentCol\"><p>The goal of the project was to translate a multiple biomarker biosensor prototype device developed at the NSF Nanoscale Science and Engineering Center for High-rate Nanomanufacturing (CHN) to the market place. Also, to help inform students and researchers involved in the development of the prototype device to understand innovation and entrepreneurship. This prototype is an Enzyme Linked Immunosorbent Assay (ELISA) based revolutionary biosensor platform that is capable of simultaneously detecting very low concentrations of various biomarkers with minimal false positives and false negatives. This biosensor device will enable early detection and monitoring of diseases and potentially save many lives and improve healthcare. Currently, there is a need for a cost effective, highly sensitive sensor for detecting multiple biomarkers simultaneously with minimal false positives to significantly enhance the possibility of early detection and to reduce the cost associated with screening and monitoring. The existing tests can measure only one type of biomarker at a time and are not sensitive enough to detect low concentrations of biomarkers for early detection or monitoring. The technologies that are capable of detecting multiple biomarkers in a single measurement are expensive and time consuming. The developed multiple biomarker biosensor prototype is envisioned to be very useful in <em>in-vitro diagnostics</em> market.</p>\n<p>&nbsp;</p>\n<p><strong>Intellectual Merits</strong></p>\n<p>The team interviewed over 70 potential customers in hospitals, <em>in-vitro</em> diagnostics companies and reference laboratories. These interview resulted in very important insights that the team found very valuable and that will help in the commercialization of the biosensor. Some of the most important findings are.</p>\n<ul>\n<li>High sensitivity, multiplex detection, and low cost device could be valuable in cancer diagnostics and monitoring. Also, high sensitivity is desirable for early detection of cardiac disease TroponinI biomarker</li>\n<li>Clinicians rely on biomarker tests for monitoring pre-operation and post-operation conditions of patients. Therefore, doctors would recommend a highly sensitive and highly specific biosensor for early detection of cancer and in monitoring efficacy of treatment such as radiotherapy using cyber-knife</li>\n<li>Roche Diagnostics suggested development of a compact and easy to use reader for point-of-care (POC) diagnostics market as well as reference laboratories</li>\n</ul>\n<p>As a result of the feedback, Biolom Delaware C-Corp for developing the biosensors was formed. Currently, Biolom is working on developing a reader/ hand-held device for POC applications, reference laboratories, and primary care. Biolom is also applying for NSF-STTR 13-547 grant for conducting prototype validation studies for early detection of cardiovascular disease biomarkers and monitoring colorectal cancer. Also, Biolom is in due-diligence with potential private angel investors to provide funding for future clinical validation studies and human clinical studies.</p>\n<p>&nbsp;</p>\n<p><strong>Broader Impact</strong></p>\n<p>The innovation knowledge and commercialization know-how learned from the I-corps program has been shared amongst graduate students at Northeastern University and that has encouraged additional teams at the Center for High-rate Nanomanufacturing start new ventures to commercialize other center applications. Currently, two collaborating teams are participating in New York and Washington DC cohorts. Commercialization of this biosensor will impact the pharmaceutical and biotechnological industries to adapt to new and advanced technologies of drug development and therapeutics. Also, it will show the effectiveness of emerging nanotechnology approaches in overcoming problems of <em>in-vitro</em> diagnostics industry. This nanotechnology-based platform will aid clinicians/physic...",
  "por_txt_cntn": "\nThe goal of the project was to translate a multiple biomarker biosensor prototype device developed at the NSF Nanoscale Science and Engineering Center for High-rate Nanomanufacturing (CHN) to the market place. Also, to help inform students and researchers involved in the development of the prototype device to understand innovation and entrepreneurship. This prototype is an Enzyme Linked Immunosorbent Assay (ELISA) based revolutionary biosensor platform that is capable of simultaneously detecting very low concentrations of various biomarkers with minimal false positives and false negatives. This biosensor device will enable early detection and monitoring of diseases and potentially save many lives and improve healthcare. Currently, there is a need for a cost effective, highly sensitive sensor for detecting multiple biomarkers simultaneously with minimal false positives to significantly enhance the possibility of early detection and to reduce the cost associated with screening and monitoring. The existing tests can measure only one type of biomarker at a time and are not sensitive enough to detect low concentrations of biomarkers for early detection or monitoring. The technologies that are capable of detecting multiple biomarkers in a single measurement are expensive and time consuming. The developed multiple biomarker biosensor prototype is envisioned to be very useful in in-vitro diagnostics market.\n\n \n\nIntellectual Merits\n\nThe team interviewed over 70 potential customers in hospitals, in-vitro diagnostics companies and reference laboratories. These interview resulted in very important insights that the team found very valuable and that will help in the commercialization of the biosensor. Some of the most important findings are.\n\nHigh sensitivity, multiplex detection, and low cost device could be valuable in cancer diagnostics and monitoring. Also, high sensitivity is desirable for early detection of cardiac disease TroponinI biomarker\nClinicians rely on biomarker tests for monitoring pre-operation and post-operation conditions of patients. Therefore, doctors would recommend a highly sensitive and highly specific biosensor for early detection of cancer and in monitoring efficacy of treatment such as radiotherapy using cyber-knife\nRoche Diagnostics suggested development of a compact and easy to use reader for point-of-care (POC) diagnostics market as well as reference laboratories\n\n\nAs a result of the feedback, Biolom Delaware C-Corp for developing the biosensors was formed. Currently, Biolom is working on developing a reader/ hand-held device for POC applications, reference laboratories, and primary care. Biolom is also applying for NSF-STTR 13-547 grant for conducting prototype validation studies for early detection of cardiovascular disease biomarkers and monitoring colorectal cancer. Also, Biolom is in due-diligence with potential private angel investors to provide funding for future clinical validation studies and human clinical studies.\n\n \n\nBroader Impact\n\nThe innovation knowledge and commercialization know-how learned from the I-corps program has been shared amongst graduate students at Northeastern University and that has encouraged additional teams at the Center for High-rate Nanomanufacturing start new ventures to commercialize other center applications. Currently, two collaborating teams are participating in New York and Washington DC cohorts. Commercialization of this biosensor will impact the pharmaceutical and biotechnological industries to adapt to new and advanced technologies of drug development and therapeutics. Also, it will show the effectiveness of emerging nanotechnology approaches in overcoming problems of in-vitro diagnostics industry. This nanotechnology-based platform will aid clinicians/physicians to learn and understand how to address low sensitivity and high specificity detection of diseases at early stages. This would eventually help in changing the treatment modality and make healthcare more effe..."
 }
}